# DENALI-1 (NCT06682793)

> A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

No report yet. It can be ordered.

- Drugs tested: A2B395

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06682793
- Phase: PHASE1, PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: A2 Biotherapeutics Inc.
- Conditions: Solid Tumor, Adult; Colorectal Cancer; Non-Small Cell Lung; NSCLC (Non-small Cell Lung Cancer); Cancer; Colon Cancer; Rectal Cancer; Lung Cancer; CRC; Head and Neck Squamous Cell Cancer; HNSCC; Renal Cell Carcinoma; RCC; Kidney Cancer; Triple Negative Breast Cancer; TNBC; Colorectal Adenocarcinoma
- Interventions: A2B395; xT CDx with HLA-LOH assay
- Enrollment: 240
- Primary outcome: Phase 1: Rate of adverse events and dose limiting toxicities (DLTs) by dose level
- Primary outcome: Phase 1: Recommended phase 2 dose (RP2D)
- Primary outcome: Phase 2: The overall response rate (ORR) for patients

## Indexed commentary on DENALI-1 so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 4 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=denali-1-nct06682793
